3. RESULTS
As shown in Fig.1 (PRISMA flow chart), summarizes the selection of studies. A total of 3063 citations were identified from databases, including PubMed, Web of Science and Embase, there were 1652 duplicates. After screening the title and abstract, 1241 citations were removed. Full-text copies of twelve articles could not be achieved and 158 full-text studies were finally reviewed. 113 studies excluded due to no safety index. Detailed exclusion reasons for other studies are shown in figuer1. Eventually, 28 studies were included in the final meta-analysis. Studies characteristics of the selected are shown inTable 1 [12-14, 16-40].
Of the 28 articles included in the final analysis, 31cohort,129980 patients notified total adverse events after COVID-19 vaccination in patients with ANC. The diseases included were: MS (17/31, 54.8%), MG (10/31, 32.3%), and NMOSD (4/31, 12.9%). studies reported the incidence of adverse reactions after the first, second, and third dose vaccination was 20(71.4%),17(60.7%),6(21.4%)respectively. For different vaccine types, mRNA vaccines (either Pfizer-BioNTech or Moderna) accounted for 46.4%, inactivated vaccines (CoronaVac, Sinovac) accounted for 14.3%, and mixed vaccination types accounted for 39.3%.